Results 31 to 40 of about 107 (101)
Медицинский совет, 2014 The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF).
V. A. Parfyonov, S. V. Verbitskaya
doaj +1 more source
, 2017 Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with ...
E. P. Panchenko +3 more
core +1 more source
Practical aspects of apixaban use in clinical practice: continuing the theme
Рациональная фармакотерапия в кардиологии, 2015 Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 and/or P-glycoprotein (P-gp) inhibitors. Analysis of clinical and pharmacological studies suggests that apixaban dose should be reduced to 2.5 mg twice ...
S. N. Bel'diev
doaj +1 more source
CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN
Атеротромбоз, 2015 The article presents the review of clinical studies that determined the role of apixaban in the early treatment and long-term secondary prophylaxis of deep vein thrombosis and lower limbs and and/or pulmonary arteries embolism.
I. S. Yavelov
doaj +1 more source
, 2020 Introduction. The direct oral anticoagulants (DOC) therapy does not require alaboratory control; however, it may be required to determine the anticoagulationlevel to choose a treatment strategy if alarge bleeding is developing or emergency surgery is ...
A. B. Dobrovolsky +3 more
core +1 more source
, 2023 Due to the continued risk of recurrence after a first episode of proximal deep vein thrombosis (DVT) of the lower extremities and/ or pulmonary embolism (PE) occurring without major transient risk factors, long-term use of anticoagulants is indicated in ...
И. С. Явелов, I. S. Yavelov
core +1 more source
ПРОБЛЕМА ВНУТРИЧЕРЕПНЫХ КРОВОИЗЛИЯНИЙ НА ФОНЕ ПРИЕМА «НОВЫХ» АНТИ КОАГУЛЯНТОВ
Атеротромбоз, 2014 Высокая распространенность тромботических осложнений у пациентов с сердечно-сосудистыми заболеваниями обусловила широкое применение в клинической практике антикоагулянтной терапии. Длительное время основным антикоагулянтом, применяемым по этим показаниям,
doaj +1 more source
Минимизация риска кровотечений при назначении прямых пероральных антикоагулянтов
, 2021 This review is devoted to the safety issues of anticoagulant therapy prescribed for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Direct oral anticoagulants are considered worldwide in accordance with the guidelines
Т. N. Novikova +1 more
core +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Data on the problem of thromboembolic complications in non-valvular atrial fibrillation are presented. Peculiarities of anticoagulant therapy to prevent thromboembolic complications, the difficulties in drug choice and dosage adjustment are also ...
E. L. Dolgova +2 more
doaj +1 more source
, 2023 This review examines the position of apixaban among other direct oral anticoagulants in patients with atrial fibrillation (AF) and venous thrombosis in randomized clinical trials and real clinical practice.
E. Р. Panchenko +1 more
core +1 more source